

# Setipiprant

**Catalog No: tcsc4940**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg



## Specifications

**CAS No:**

866460-33-5

**Formula:**

$C_{24}H_{19}FN_2O_3$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 36$  mg/mL (89.46 mM)

**Alternative Names:**

ACT-129968;KYTH-105

**Observed Molecular Weight:**

402.42


**Product Description**

Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.

IC50 value: 6.0 nM

Target: PGD2

in vitro: Setipiprant is an orally available, selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T helper [Th]-2 cells) antagonist. CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells. Thus, antagonism of CRTH2 receptors is considered to be a promising therapeutic target for various allergic diseases and asthma.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!